risankizumab · Skyrizi

Monoclonal antibody

Also known as BI 655066, ABBV-066

Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis, Crohn's Disease (label: moderately to severely active CD or UC who have had an inadequate response to, lost response to, or...), Ulcerative Colitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (10)
EU
  • Moderately to severely active ulcerative colitis in adultspmlive.com
  • Moderately to severely active Crohn's disease in adultsnews.abbvie.com
  • Moderate to severe plaque psoriasis in adults (initial EU authorisation; PsA, Crohn's disease and ulcerative colitis added later)EMA
Product first approved 2019
JP
  • Moderately to severely active ulcerative colitis, induction and maintenance, where existing therapy is inadequatekyodonewsprwire.jp
  • Moderately to severely active Crohn's disease (IV 600 mg and SC 360 mg autodoser) where existing therapy is inadequatekyodonewsprwire.jp
  • Plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults with inadequate response to conventional therapies (first approval worldwide)antibodysociety.org
Product first approved 2019
KR
  • Moderately to severely active Crohn's disease in adults
Product first approved 2023pearceip.law
UK
  • Moderately to severely active Crohn's disease and ulcerative colitis
Product first approved 2022medicines.org.uk
CA
  • Moderately to severely active Crohn's disease (authorised in Canada since October 2022, per Health Canada)
  • Active psoriatic arthritis in adults (authorised in Canada since March 2022, per Health Canada)
Product first approved 2022dhpp.hpfb-dgpsa.ca

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (31)
Crohn's Disease
NCT07499232 · Janssen Research & Development, LLC
2026-04-21 – 2030-12-11 · Crohn Disease
What this study did
Psoriasis
NCT03219437 · AbbVie
2018-07-30 – 2021-11-26 · Psoriasis
What this study did
NCT03478787 · AbbVie
2018-05-08 – 2020-07-08 · Psoriasis
What this study did
NCT03518047 · AbbVie
2018-07-19 – 2020-02-11 · Psoriasis
What this study did
Psoriatic Arthritis
Ulcerative Colitis
NCT07071519 · AbbVie
2025-07-28 – 2034-07 · Ulcerative Colitis
What this study did
NCT07177118 · First Affiliated Hospital of Wenzhou Medical University
2025-10-20 – 2028-10-20 · Crohn Disease, Crohn Disease and Ulcerative Colitis
What this study did
Other / comorbidity
Phase 2/3 (1)
Phase 2 (17)
Crohn's Disease
NCT06548542 · AbbVie
2024-09-04 – 2030-01 · Crohn's Disease
What this study did
NCT02513459 · AbbVie
2015-09-16 – 2019-06-19 · Crohn Disease
What this study did
Psoriasis
NCT05283135 · Oregon Medical Research Center
2022-03-01 – 2024-07-10 · Psoriasis
What this study did
NCT03000075 · AbbVie
2016-12-02 – 2018-06-20 · Psoriasis
What this study did
NCT02054481 · Boehringer Ingelheim
2014-02 – 2015-07 · Psoriasis
What this study did
Psoriatic Arthritis
NCT06865105 · AbbVie
2025-04-11 – 2029-08 · Psoriatic Arthritis
What this study did
NCT02986373 · AbbVie
2016-12-15 – 2018-07-30 · Psoriatic Arthritis
What this study did
NCT02719171 · AbbVie
2016-04 – 2017-08 · Arthritis, Psoriatic
What this study did
Ulcerative Colitis
NCT07697456 · AbbVie
2026-07-31 – 2031-10 · Crohn's Disease, Ulcerative Colitis
What this study did
Other / comorbidity
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT04583956 · National Institute of Allergy and Infectious Diseases (NIAID)
2020-10-23 – 2021-09-13 · COVID-19
What this study did
NCT03926169 · AbbVie
2019-06-03 – 2021-08-02 · Hidradenitis Suppurativa
What this study did
NCT02443298 · AbbVie
2015-06-23 – 2018-02-02 · Asthma
What this study did
NCT02047110 · AbbVie
2014-01-28 – 2016-07-25 · Ankylosing Spondylitis (AS)
What this study did
Phase 1/2 (2)
Ulcerative Colitis
NCT07258641 · University Medical Center Groningen
2026-01-15 – 2028-04-01 · Ulcerative Colitis (UC), Crohn Disease (CD)
What this study did
NCT06606808 · University Medical Center Groningen
2024-11-08 – 2025-12 · Ulcerative Colitis (UC), Crohn Disease (CD)
What this study did
Phase 1 (19)
Psoriasis
NCT01577550 · AbbVie
2012-04 – 2014-05 · Psoriasis
What this study did
Psoriatic Arthritis
NCT05083078 · Janssen Research & Development, LLC
2021-11-04 – 2022-07-01 · Arthritis, Psoriatic, Healthy
What this study did
Ulcerative Colitis
Other / comorbidity
NCT07466550 · AbbVie
2026-06-04 – 2027-01 · Healthy Volunteer
What this study did
NCT06487572 · AbbVie
2024-07-23 – 2025-02-07 · Healthy Volunteers
What this study did
NCT06054425 · AbbVie
2023-11-20 – 2024-05-06 · Healthy Volunteers
What this study did
NCT05567029 · AbbVie
2022-09-28 – 2023-04-20 · Healthy Volunteers
What this study did
NCT05274100 · AbbVie
2020-09-01 – 2021-07-06 · Healthy Volunteers
What this study did
NCT05268068 · AbbVie
2019-06-27 – 2020-04-26 · Healthy Volunteers
What this study did
NCT05283681 · AbbVie
2019-04-02 – 2019-11-11 · Healthy Volunteers
What this study did
NCT05305222 · AbbVie
2017-10-23 – 2018-06-15 · Healthy Volunteers
What this study did
NCT05283694 · AbbVie
2017-09-11 – 2018-06-12 · Healthy Volunteers
What this study did
Phase 4 (10)
Crohn's Disease
NCT07872449 · Yuki Horio
2026-10-01 – 2029-03-31 · Crohn Disease, Perianal Fistula, Perianal Fistula Due to Crohn's Disease, Perianal Crohn's Disease
What this study did
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT04630652 · Jaehwan Kim
2021-04-07 – 2025-05-13 · Psoriasis
What this study did
NCT04340076 · Radboud University Medical Center
2020-08-20 – 2025-01-31 · Psoriasis, Psoriasis Vulgaris
What this study did
NCT05685940 · University Hospital, Ghent
2020-04-05 – 2024-12-31 · Psoriasis Vulgaris
What this study did
NCT04722640 · Istituto Clinico Humanitas
2021-01-25 – 2022-01-31 · Psoriasis
What this study did
Ulcerative Colitis
NCT06346288 · AbbVie
2024-04-24 – 2026-02-05 · Inflammatory Bowel Disease
What this study did
Early phase / not applicable (1)
Crohn's Disease
NCT06298188 · Shaare Zedek Medical Center
2024-10-31 – 2026-10 · Crohn Disease
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Psoriatic Arthritis
NCT06641089 · MoonLake Immunotherapeutics AG
2024-10-15 – 2027-09-13 · Arthritis, Psoriatic
What this study did
NCT06624228 · UCB Biopharma SRL
2024-10-21 – 2026-06-03 · Psoriatic Arthritis
What this study did
Phase 1 (1)
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Psoriasis
NCT07933536 · AbbVie
2026-12-03 – 2028-12 · Moderate to Severe Psoriasis
What this study did
Phase 4 (1)
Crohn's Disease
NCT05928039 · University of Calgary
2023-10-25 – 2028-12-31 · Crohn Disease
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Crohn's Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Risankizumab (Skyrizi): this drugApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03104413: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1))
NCT03105128: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Period 1) 24.6% (95% CI 18.2-31.0) vs Risankizumab 600mg (Period 1) 45.2% (95% CI 39.9-50.5) vs Risankizumab 1200mg (Period 1) 41.6% (95% CI 36.3-46.8); p=<0.001 (Placebo (Period 1) vs Risankizumab 600mg (Period 1)), p=<0.001 (Placebo (Period 1) vs Risankizumab 1200mg (Period 1))
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT02499783: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg)
NCT02065570: Percentage of Participants Who Achieved Clinical Remission at Week 4 (Week 4): Induction: Standard Induction Dose 43.7% vs Induction: Higher Induction Dose 43.5%; p=0.939 (Induction: Standard Induction Dose vs Induction: Higher Induction Dose) missed
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02871635: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol).
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Entocort EC)ApprovedSmall moleculeGlucocorticoid receptorWeak signalFeatured results are safety only in this race
Budesonide (Ortikos)
ApprovedUS marketing discontinued
—Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signal
NCT00552058: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported missed
NCT00297648: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments (Baseline, Week 10): CDP870 400 mg -6.47 score on a scale (95% CI -7.6 to -5.34)
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00094458: Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine)
NCT00269841: Primary end point achieved by 68% (5 mg/kg) and 56% (10 mg/kg) vs 26% on placebo (P=0.002 and P=0.02).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02096861: CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03926130: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab)
Natalizumab (Tysabri)ApprovedMonoclonal antibodyα4 integrinPartial signal
NCT00032799: Week 10 clinical response (CDAI decrease >=70): natalizumab 56% vs placebo 49% (P=0.05); remission (CDAI <150): 37% vs 30% (P=0.12) missed
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03345849: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Placebo 29.1% (95% CI 22.4-35.8) vs Upadacitinib 45 mg QD 49.5% (95% CI 44.2-54.8); p=<0.0001 (Placebo vs Upadacitinib 45 mg QD)
NCT03345836: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Part 1 (Double Blind): Placebo 21.1% (95% CI 14.9-27.2) vs Part 1 (Double Blind): Upadacitinib 45 mg 38.9% (95% CI 33.6-44.2); p=<0.0001 (Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT01369355: Number of Participants With Clinical Remission at Week 44 (Week 44): Placebo Subcutaneously (SC) 47/131 (35.9%) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w) 63/129 (48.8%) vs Ustekinumab 90 mg SC q8w 68/128 (53.1%); p=0.040 (Placebo Subcutaneously (SC) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)), p=0.005 (Placebo Subcutaneously (SC) vs Ustekinumab 90 mg SC q8w)
NCT01369342: Number of Participants With Clinical Response at Week 6 (Week 6): Placebo 60/209 (28.7%) vs Ustekinumab 130 mg 108/209 (51.7%) vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg) 116/209 (55.5%); p=< 0.001 (Placebo vs Ustekinumab 130 mg), p=< 0.001 (Placebo vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg))
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinPartial signal
NCT02611817: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 34.3% (95% CI 26.3-43.0) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 48.0% (95% CI 42.0-54.1); p=0.008 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
NCT03234907: Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 (Week 10): Induction Phase: Placebo 24.3% (95% CI 14.8-36.0) vs Induction Phase: Vedolizumab 300 mg 19.4% (95% CI 13.3-26.9); p==0.347 (Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg) missed
AfimkibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 3Cell therapyAllogeneic MSC therapyPartial signalNo reviewed efficacy summary in this indication
TH-SC01Phase 3Cell therapyMesenchymal stem cells (MSC)Weak signalNo reviewed efficacy summary in this indication
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 2/3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorPartial signal
NCT02378688: Proportion achieving CDAI-100 response at Week 12: amiselimod 0.4mg 19/39 (48.7%) vs placebo 20/37 (54.1%); odds ratio 0.79, 95% CI [0.31, 1.98], not statistically significant. missed
AVB-114Phase 2Cell therapyImplantable cell/biomaterial constructPartial signal
NCT04847739: Combined remission at 9 months: 45.8% (11/24) with AVB-114 vs 8.3% (2/24) with standard of care; difference 38% (95% CI 11 to 60%) (2025-10-29).
AZD7798Phase 2Monoclonal antibodyCCR9Weak signalFeatured results are safety only in this race
ExoFloPhase 2Cell therapyMSC-derived exosomesWeak signalFeatured results are safety only in this race
Golimumab (Simponi)Phase 2Monoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 2Small moleculemiR-124not yet gradedNo reviewed efficacy summary in this indication
OmilancorPhase 2Small moleculeLANCL2not yet gradedNo reviewed efficacy summary in this indication
ZotemtegrastPhase 2Small moleculeα4β7 integrinnot yet gradedNo reviewed efficacy summary in this indication
EcoActivePhase 1/2Microbiome therapeuticBacteriophage (anti-AIEC)not yet gradedNo reviewed efficacy summary in this indication
Furestem-CDPhase 1/2Cell therapyAllogeneic MSC therapyWeak signalNo reviewed efficacy summary in this indication
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ALLO-ASCPhase 1Cell therapyAdipose-derived MSC therapyWeak signalNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Hemay007Phase 1Small moleculeTNF-alphaWeak signalNo reviewed efficacy summary in this indication
HRS-7085Phase 1Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
IPG11406Phase 1Small moleculeEBI2Weak signalFeatured results are safety only in this race
LMT503Phase 1Small moleculeMacrophage polarization / Cellular metabolismnot yet gradedNo reviewed efficacy summary in this indication
OD-07656Phase 1Small moleculeRIPK2Weak signalNo reviewed efficacy summary in this indication
TQH3906Phase 1Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 64 furthest-along competitors are listed; 7 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

6 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(18 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Skyrizi (risankizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
January 2027 (1)
Phase 1Healthy VolunteerRecruiting
Est. primary completion 2027-01 · NCT07466550 · CT.gov ↗
What to watch
March 2027 (1)
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2027-03 · NCT06063967 · CT.gov ↗
What to watch
August 2027 (1)
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2027-08 · NCT06880744 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1/2Crohn's DiseaseNot yet recruiting
Est. primary completion 2027-12-31 · NCT07258641 · CT.gov ↗
What to watch
2028 (7)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
February 2028 (1)
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2028-02 · NCT04524611 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3PsoriasisActive not recruiting
Est. primary completion 2028-04 · NCT04862286 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Crohn's DiseaseNot yet recruiting
Est. primary completion 2028-06-20 · NCT07177118 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2028-09 · NCT03398135 · CT.gov ↗
What to watch
October 2028 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2028-10-13 · NCT07872449 · CT.gov ↗
What to watch
November 2028 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2028-11-15 · NCT07499232 · CT.gov ↗
What to watch
2029 (3)
February 2029 (1)
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2029-02 · NCT03105102 · CT.gov ↗
What to watch
April 2029 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2029-04 · NCT05995353 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Psoriatic ArthritisRecruiting
Est. primary completion 2029-08 · NCT06865105 · CT.gov ↗
What to watch
2030 (2)
January 2030 (1)
Phase 2Crohn's DiseaseRecruiting
Est. primary completion 2030-01 · NCT06548542 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 2Crohn's DiseaseRecruiting
Est. primary completion 2031-10 · NCT07697456 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Phase 3Ulcerative ColitisRecruiting
Est. primary completion 2034-07 · NCT07071519 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 October 2026ApprovalFDA approves SC induction regimen for Skyrizi in Crohn's disease
US, FDA · Source ↗